Mission | Scientific Advisory Board
Mission
AngloEast StemCell Therapy offers the very latest in therapy to help patients who have been told that there is little the medical profession can do to help them.
We offer hope to people who refuse to accept that they must live their remaining days condemned to being incapacitated and restricted in their activities and pleasures because they cannot avail themselves of the latest medical technologies in their own country.
Our core values are to demonstrate excellence, compassion and integrity in all that we do. We are committed to the highest professional, ethical and moral standards to work with and for our patients and we will do our utmost to return them to health.
The patients and our own goals will be achieved by the development and use of cellular therapies using autologous cells cells that originate from the person to whom the cells in enriched form will be administered. There is absolutely no danger of immunological incompatibility between donor and host because they are a perfect DNA match.
Although cellular therapy strategies, such as bone marrow transplants, have existed for many years, the principle of using autologous (the patient's own) cells processed outside of the body has only recently been extensively explored. This concept has been proven safe and effective in numerous animal and clinical trials. It has been tested in a variety of conditions, such as cancer, cardiovascular disorders, and even spinal cord injury. AngloEast StemCell Therapy and its mother company has mastered this technology. AngloEast StemCell Therapy, in combination with the considerable clinical wisdom of our medical associates, is now adapting this technology to address a variety of medical disorders which have hitherto been considered as incurable.
The AngloEast StemCell Therapy Advantage
First and foremost, we give our patients access to therapeutic modalities of the highest standards. Our treatments are based on the discoveries of world-renowned scientists, but due to the cumbersome and prolonged formalities required for official approval in some countries, are not yet in practice. Patients all over the world cannot wait for those formal procedures to run their course, they need these therapies NOW. Consequently, we work hand in hand with senior and experienced physicians and scientists to make these therapies available without delay, after proper clinical trials and within an established regulatory framework.
Secondly, AngloEast StemCell Therapy has the professional know-how and expertise required to process and tame ex vivo cells and bring them to a predetermined state of therapeutic activity. Utilizing advanced cellular technologies of handling, controlling, growth, differentiating, and manufacturing processes we focus on specific cellular subpopulations which are of specific therapeutic benefit to the conditions we wish to treat. At the end of this tightly controlled and regulated process we achieve a highly potent, safe, and quality-controlled therapeutic product ready for administration.
Therapy
Cardiologists and cardiac surgeons are currently using StemCell. AngloEast StemCell Therapy's leading cell therapy product which contains autologous expanded Angiogenic Cell Precursors (ACPs) to improve the quality of life of patients by relieving debilitating symptoms such as severe agina pectoris ( chest pain) and increasing exercise tolerance. Currently being treated are patients suffering from Ischemic Heart Disease (or coronary artery disease) Cardiomyopathy and Congestive Heart Failure.
This use of ACPs as a microrevascularization process (as opposed to the macrorevascularization techniques like coronary bypass and angioplasty) is aimed at promoting the formation of natural bypass blood vessels within the ischemic, but not yet scarred tissue, thus alleviating the clinical condition of these patients. Patients who have exhausted all other treatment options such as coronary artery bypass surgery (CABG) or balloon angioplasties are candidates. If the patient has other medical conditions which make these conventional procedures too risky or otherwise not possible, stem cell therapy will probably be a viable alternative.
All procedures are performed by medical professionals at the various hospitals affiliated with AngloEast StemCell Therapy. Each procedure starts at the hospital with a medical examination. Then, in a process similar to donating blood, about one-half pint of blood is drawn and couriered to our lab under strictly controlled conditions. Because there are far too few stem cells in anyone's blood to be sufficiently effective, AngloEast StemCell Therapy developed a proprietary technology to selectively increase the miniscule number of stem cells harvested from the patient's blood and turn them into millions of ACPs. This takes about a week. When StemCell is returned from the lab, a cardiologist or a cardiac surgeon injects the cells into one of the patient's coronary arteries or implants them directly into the patient's heart depending upon his clinical judgment. Once in place, these cells now have the potential to build new blood vessels and heart muscle. While it is not expected that the patient will see or feel any improvement within the first few weeks after the administration, in some patients this may occur quite soon. Within a month, sometimes two, the patient should experience less chest pain as well as a marked increase in exercise tolerance. The result, as far as the patient is concerned, is an improved quality of life.
2. Scientific Advisory Board <Go to top>
We have developed a close relationship with leading scientists and physicians in our fields of operations and will have the capability, the scientific skills and the resources to offer these therapies to those courageous people who have few viable options and are willing to take calculated risks to try experimental treatments that can significantly alleviate or even cure the severe disorders that they suffer from.
Professor Alexander Battler
Professor Battler received his MD from the Hebrew University
and Hadassah Medical School in 1972. He was the founder and first director
of the Neufeld Cardiac Research Institute of the Sackler Faculty of Medicine,
Tel Aviv University and Sheba Medical Center. In 1993, he became director
of the Cardiology Department of the Soroka Medical Center in Beer Sheba,
the incumbent of the Andre Feher Chair of Cardiology and Professor of
Cardiology at the Faculty of Health Sciences of Ben Gurion University.
In 1996, he was appointed Chairman of the Ben Gurion University Cardiac
Research Center. He is currently the Director of the Cardiology Department
at the Rabin Medical Center. He is also Professor and Chairman of Cardiology
at the Sackler Faculty of Medicine, Tel Aviv University.
In addition to his clinical and academic activities Prof. Battler is Chairman
of the Israeli National Council for Prevention and Treatment of Cardiac
and Cardiovascular Diseases. He is also the Chairman of the PR Committee
and Board Member of the European Society of Cardiology. Professor Battler
is the Past President of the International Society of Cardiovascular Pharmacotherapy
and of the Israel Heart Society.
Prof. Battler is the author of more than 150 original articles, and is
a frequently invited lecturer at international meetings. His main fields
of research include regenerative cardiology, intramyocardial therapies,
and myocardial remodeling. He was one of the first cardiologists in the
world to use cellular therapy for heart disorders.
Professor Michael Belkin
Michael Belkin is a Professor of Ophthalmology at Tel Aviv University
and the director of the Ophthalmic Technologies Laboratory at the University's
Eye Research Institute at the Sheba Medical Center. He was awarded a master's
degree in science by Cambridge University, England, and received a doctorate
in medicine from the Hebrew University of Jerusalem. Prof. Belkin served
previously as:
1. Founder and first full-time director of the Tel Aviv University Eye
Research Institute
2. Chairman of the Tel-Aviv University Department of Ophthalmology
3. President of the Israel Society of Eye and Vision Research of which
he was one of the founders.
Dr. Belkin is an active, long-standing member of the Association for Research
in Vision and Ophthalmology (ARVO), the American Academy of Ophthalmology,
the International Society of Eye Research, the Biomedical Optics Society
section of the International Society of Optical Engineering (SPIE), the
American Glaucoma Society, and many others. He is the author of over 200
scientific publications that received various research awards. He has
served and is serving as chairman and member of various international
professional committees and scientific journals' editorial boards.
Professor Suphachai Chaithiraphan
Professor Suphachai Chaithiraphan received his MD from the Faculty
of Medicine, Siriraj Hospital in1964 and was received as a diplomat of
Internal Medicine & Cardiovascular Disease Specialist from the United
States of America; Professor Suphachai served and is serving as President
and member of various national and international professional societies
as follows:
Former Committee of The Medical Council of Thailand
President of Thai Atherosclerosis Society
President of The Heart Association of Thailand under The Royal Patronage
Former President of The Royal College of Physician of Thailand, under
The Royal Patronage
The Secretary General of Thailand Heart Foundation under The Royal Patronage
Fellow, Royal College of Physicians ( London )
Fellow, American College of Physicians (FACP)
Fellow, American College of Cardiology (FACC)
Fellow, American College of Chest Physicians (FACCP)
Fellow, Royal Australian College of Physicians (FRACP)
He is currently Chairman of the Executive Board of Chao Phya Hospital
Public Company Limited and Director of The Chao Phya Cardiac Unit. He
is also a consultant to the Cardiac Center, Bangkok General Hospital,
BNH Hospital, and Siriraj Hospital.
Professor Aaron Ciechanover
Professor Ciechanover received his MD from Hebrew University
and Hadassah Medical School, Jerusalem, Israel in 1974 and was a graduate
in D. Sc. from Technion-Israel Institute of Technology, Haifa, Israel
in 1981. He was the Director of The Rappaport Family Institute for Research
in the Medical Sciences at Technion-Israel Institute of Technology and
is currently serving as a Distinguished Professor at the same place. Recognized
as one of the best experts in biochemistry, Professor Ciechanover is frequently
invited as a visiting professor to many renowned academic institutions
worldwide and is a permanent member of several national and international
associations such as The Council of the European Molecular Biology Organization
(EMBO), Asia-Pacific International Molecular Biology Network (IMBN), European
Academy of Arts and Sciences, etc.
Professor Ciechanover has authored more than 150 scientific articles and
patents. He was granted the Nobel Prize for Chemistry in 2004 together
with Prof. Avram Hershko and Prof. Irwin Rose for the discovery of the
ubiquitin intracellular pathway.
Professor Tsvee Lapidot
Prof. Tsvee Lapidot, a renowned expert in the field of hematopoietic
stem cells holds the Edith Stein Immunology chair at the Weizmann Institute
of Science, Israel. He is a member of the American Society of Hematology
and the International Society of Experimental Hematology. Prof. Lapidot
is on the editorial boards of several leading scientific hematology journals
and has received numerous awards for his scientific achievements. He is
widely recognized as a human stem cell biology expert, having participated
in the development of a pre-clinical immune deficient (NOD/SCID) mouse
model for normal and leukemic human stem cells. He has published many
articles on stem cell biology in leading journals such as Science and
Nature Immunology and has been an invited speaker at important scientific
conferences. Prof. Lapidot holds MA and PhD degrees from The Weizmann
Institute.
Professor Ren-Ke Li
Professor Ren-Ke Li is Professor of Surgery in the Department
of Cardiac Surgery at the University of Toronto, and also heads a research
group at the Division of Experimental Therapeutics, Toronto General Hospital
Research Institute. He is a leader in the development of cell therapies
for cardiovascular diseases, and one of the pioneers in the field. Professor
Li is the author of numerous articles on the subject in prestigious scientific
and medical journals.
Professor John Marshall
Professor Marshall graduated from London University in 1965
and received his Ph. D in 1968. During 1982 - 1991, Professor Marshall
was the Sembal Professor of Experimental Ophthalmology at the Institute
of Ophthalmology. Presently, he is serving as the Frost Professor of Ophthalmology,
Chairman of the Academic Department of Ophthalmology at St. Thomas's Hospital,
and Chairman of the Medical and Scientific Advisory Board, and Trustee
of the British Retinitis Pigmentosa Society. Professor Marshall has been
pursuing his research concerning the development of lasers for ophthalmic
diagnosis and surgery for thirty years, leading to the emergence of the
Excimer laser for correcting refractive disorders and the first Diode
laser for treating eye problems among patients with diabetes, glaucoma,
and aging.
Professor Marshall has been awarded from many renowned medical institutes
worldwide such as the Nettleship Medal of the Ophthalmologic Society of
the United Kingdom, the Barraquer Medal of the International Society of
Cataract and Refractive Surgery, the Kelman Innovator Award of the American
Society for Refractive and Cataract surgery, the Lim Medal of the Singapore
National Eye Centre, etc.
Professor Naphtali Savion
Prof. Savion holds a Doctorate in Biochemistry from the Hebrew
University of Jerusalem and held a postdoctoral fellowship at the Cancer
Research Institute of the University of California. For the past 20 years
he has led a research group at Tel Aviv University which was awarded $850,000
for its research activities, and has led other R&D projects with a
total budget of over $1.6 million. He has published over 120 papers in
leading professional journals and has participated in more than 60 international
meetings. He registered four patents and is one of the Founders of the
Start-Up company Matis Medical. Prof. Savion is a cell biology expert,
who specializes in the fields of vascular biology, growth factors, bone
cells in culture, and cells-extracellular matrix interaction. Prof. Savion
is serving as a scientific consultant to several life science companies.